Lv1
50 积分 2022-09-27 加入
Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha–Positive, PIK3CA-Mutant Breast Cancer
4个月前
已完结
Metronomic chemotherapy and breast cancer: a critical evaluation of its role in the new landscape of therapeutics
4个月前
已完结
Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer
4个月前
已完结
Trastuzumab Deruxtecan in HER2-Positive Breast Cancer with HER2 Loss After Dual-Target Adjuvant Therapy: A Case Report
6个月前
已关闭
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer
7个月前
已完结
Systemic treatment for hormone receptor-positive/HER2-negative advanced/metastatic breast cancer: A review of European real-world evidence studies
11个月前
已完结
Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors
11个月前
已完结
The PARTNER trial of neoadjuvant olaparib in triple-negative breast cancer
1年前
已完结
PARP Inhibitors for Breast Cancer Treatment
1年前
已完结
Incidence of antibody–drug conjugate-related fatigue in patients with breast cancer: A systematic review and meta-analysis
1年前
已完结
皖公网安备34019202002308
